News - Biogen Idec


Current filters:

Biogen Idec

Popular Filters

55 to 79 of 105 results

Elan to unlock benefits for shareholders from Tysabri deal


The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Merck & Co in biosimilars deal with Samsung Bioepis


US pharma giant Merck & Co (NYSE: MRK) has entered into an agreement with South Korea-based Samsung Bioepis…

Biogen IdecBiotechnologyMerck & CoPharmaceuticalProductionResearchSamsung Bioepis

Elan sells its Tysabri rights to Biogen; posts 2012 financials


Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

Biogen Idec 4th-qtr sales up 7% but earnings fall short of expectations


US biotech firm Biogen Idec (Nasdaq: BIIB) posted fourth-quarter and full-year 2012 results, with generally-accepted…

Biogen IdecBiotechnologyFinancial

Biogen Idec files for US approval of hemophilia B treatment


US biotech firm Biogen Idec (Nasdaq: BIIB) on Friday announced it has submitted a Biologics License Application…

Biogen IdecBiotechnologyNorth AmericaRegulationrFIXFcrFVIIIFcSwedish Orphan Biovitrum

Biogen Idec to drop ALS drug after failure in Ph III trial


Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) fell as much as 8% to $138.05 in pre-market trading…

Biogen IdecBiotechnologydexpramipexoleNeurologicalResearch

Biogen Idec and Isis Pharma in up to $230 million antisense deal


USA-based companies Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

News briefs from Sanofi, Biogen/SOBI and Novartis


French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent


US biotech firm Biogen Idec (Nasdaq: BIIB) and partner Swedish Orphan Biovitrum (STO: SOBI) have announced…

Biogen IdecBiotechnologyEuropeNorth AmericaPharmaceuticalRare diseasesRegulationResearchrFIXFcSobiSwedish Orphan Biovitrum

Positive trial results for Biogen Idec's MS drug BG-12


US biotech firm Biogen Idec (Nasdaq: BIIB) says that data from the Phase III DEFINE and CONFIRM studies…

BG-12Biogen IdecBiotechnologydimethyl fumarateNeurologicalResearch

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million


US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients


In the USA, 77% of surveyed neurologists have experience with the STRATIFY JCV assay - commercially available…

AvonexBiogen IdecElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalTysabri

Biogen Idec 2nd-qtr sales and earnings top analysts expectations


US biotech firm Biogen (Nasdaq: BIIB) pleased markets with its second-quarter 2012 financial results,…

Biogen IdecBiotechnologyFinancial

Biogen Idec and Isis Pharma ink deal on targeting myotonic dystrophy


In a second accord between the US biotech companies this year, Biogen Idec (Nasdaq: BIBB) and Isis Pharmaceuticals…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingRare diseasesResearch

New analysis of risk stratification for Biogen and Elan's Tysabri


US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a…

Biogen IdecBiotechnologyElanNeurologicalPharmaceuticalResearchTysabri

55 to 79 of 105 results

Back to top